// MedCheck — Shared constants and enums
// Phase A: modular source — concatenated by build.js

const INH_MULT = { strong: 5.0, moderate: 2.0, weak: 1.25 };
const IND_MULT = { strong: 0.15, moderate: 0.4, weak: 0.7 };

// ── DOSE TIERS: clinical dose ranges for dose-dependent inhibition modeling ──
// inhMod: multiplier applied to inhibition strength at each dose tier
// low=subtherapeutic inhibition, standard=published Ki data, high=near-saturation, max=supratherapeutic
const ACTOR_TYPE = Object.freeze({
  DRUG:          'drug',
  METABOLITE:    'metabolite',
  ENZYME:        'enzyme',
  TRANSPORTER:   'transporter',
  FOOD:          'food_compound',
  ENVIRONMENTAL: 'environmental_compound',  // toxins, pollutants, xenobiotics
  ENDOGENOUS:    'endogenous_compound',      // neurotransmitters, hormones, trace amines
  RECEPTOR:      'receptor',                // pharmacological targets (mu-opioid, 5-HT2A, D2...)
  PHENOTYPE:     'phenotype',               // observable outcomes (analgesia, serotonin_syndrome...)
});

// ── Edge Types ── (all relationship types between actors)
const EDGE_TYPE = Object.freeze({
  SUBSTRATE_OF:    'substrate_of',     // actor is metabolized by enzyme/transporter
  INHIBITS:        'inhibits',         // actor inhibits enzyme/transporter/receptor
  INDUCES:         'induces',          // actor induces enzyme/transporter expression
  METABOLIZED_TO:  'metabolized_to',   // parent → metabolite (inactive/active)
  TRANSPORTED_BY:  'transported_by',   // actor is a substrate of a transporter
  COMPETES_WITH:   'competes_with',    // two actors compete for same enzymatic/receptor site
  ACTIVATES:       'activates',        // prodrug → active metabolite; agonist → receptor
  BLOCKS:          'blocks',           // antagonist blocks receptor; efflux pump blocks CNS entry
  ACCUMULATES_IN:  'accumulates_in',   // lipophilic actor accumulates in compartment
  PRODUCES:        'produces',         // metabolic step or receptor activation → downstream effect
  SUPPRESSES:      'suppresses',       // actor suppresses phenotype/function (e.g. CYP2D6 inhibition → ↓ analgesia)
});

// ── Tissue Compartments ──
// Conceptual compartments that distinguish where a drug/metabolite acts.
// Key insight: brain CYP2D6 ≠ hepatic CYP2D6; lipophilic compounds in
// adipose behave fundamentally differently from plasma compartment.
const TISSUE_COMPARTMENT = Object.freeze({
  PLASMA:   'plasma',    // systemic circulation (PK measurements)
  LIVER:    'liver',     // primary metabolic organ; hepatic CYPs
  BRAIN:    'brain',     // CNS; brain CYP2D6, BBB gating by P-gp/BCRP
  GUT:      'gut',       // intestinal CYP3A4/P-gp first-pass extraction
  KIDNEY:   'kidney',    // renal clearance; OCT2/MATE1 transporters
  ADIPOSE:  'adipose',   // lipophilic compound depot; slow release
  PLATELET: 'platelet',  // MAO-B location; serotonin storage
});

// ── Evidence Schema ──
// Canonical evidence object used by all edges.
// Older edges may have only {confidence, sources}; new/upgraded edges
// carry full provenance. Both forms are valid — consumers should use
// evidenceConfidence() helper to extract a normalized confidence value.
const EVIDENCE_SCHEMA_VERSION = 2;

const EVIDENCE_TIER = Object.freeze({
  IN_VITRO:     'in_vitro',       // cell/microsome assay only
  ANIMAL:       'animal',         // rodent/primate PK
  CASE_REPORT:  'case_report',    // individual patient observation
  OBSERVATIONAL:'observational',  // retrospective cohort/database
  CLINICAL_PK:  'clinical_pk',    // prospective clinical PK study (gold standard for DDI)
  RCT:          'rct',            // randomized controlled trial
  META_ANALYSIS:'meta_analysis',  // quantitative synthesis of multiple studies
  GUIDELINE:    'guideline',      // evidence-based clinical guideline (CPIC, EMA, etc.)
  FDA_LABEL:    'fda_label',      // FDA-approved prescribing information (regulatory)
});

// ── Evidence Tier Weights ──
// Used by computeEdgeConfidence() and traverseEffects() decay.
// FDA label is high but not 1.0 — it reflects regulatory consensus, not always RCT quality.
// Meta-analysis can exceed FDA label for quantified pharmacokinetics.
const EVIDENCE_WEIGHT = {
  [EVIDENCE_TIER.FDA_LABEL]:    0.95,
  [EVIDENCE_TIER.META_ANALYSIS]:0.92,
  [EVIDENCE_TIER.RCT]:          0.90,
  [EVIDENCE_TIER.GUIDELINE]:    0.88,
  [EVIDENCE_TIER.CLINICAL_PK]:  0.85,
  [EVIDENCE_TIER.OBSERVATIONAL]:0.70,
  [EVIDENCE_TIER.CASE_REPORT]:  0.45,
  [EVIDENCE_TIER.ANIMAL]:       0.35,
  [EVIDENCE_TIER.IN_VITRO]:     0.30,
};

// ── GENOTYPE_PHENOTYPE — CYP metabolizer phenotype definitions ──
const GENOTYPE_PHENOTYPE = Object.freeze({
  PM: 'poor_metabolizer',
  IM: 'intermediate_metabolizer',
  NM: 'normal_metabolizer',
  UM: 'ultrarapid_metabolizer',
});

const GENOTYPE_RISK_STATUS = Object.freeze({
  ABSENT: 'risk_allele_absent',
  PRESENT: 'risk_allele_present',
});

// GENOTYPE_EFFECTS — fold-change multipliers vs NM baseline for key enzymes
// Source: CPIC guidelines, FDA labels, clinical PK studies
const GENOTYPE_EFFECTS = {
  CYP2D6: {
    [GENOTYPE_PHENOTYPE.PM]:  { auc_fold:4.5, freq_pct:7,  note:"Enzyme absent. Codeine → no morphine (analgesia failure). Tamoxifen → reduced endoxifen (<30% of NM). TCAs may accumulate dangerously." },
    [GENOTYPE_PHENOTYPE.IM]:  { auc_fold:2.0, freq_pct:11, note:"Reduced activity (~2× AUC vs NM). Allele frequencies vary substantially by ancestry; population-specific interpretation should use genotype report context." },
    [GENOTYPE_PHENOTYPE.NM]:  { auc_fold:1.0, freq_pct:75, note:"Normal metabolism (reference)." },
    [GENOTYPE_PHENOTYPE.UM]:  { auc_fold:0.3, freq_pct:7,  note:"Ultra-rapid metabolism. Reduced AUC. Codeine → excess morphine → respiratory depression. Frequency varies substantially by ancestry." },
  },
  CYP2C19: {
    [GENOTYPE_PHENOTYPE.PM]:  { auc_fold:3.0, freq_pct:3, note:"Clopidogrel prodrug not activated → stent thrombosis risk. PPIs highly elevated. Frequency varies substantially by ancestry." },
    [GENOTYPE_PHENOTYPE.IM]:  { auc_fold:1.6, freq_pct:26,note:"Partial clopidogrel activation; intermediate platelet inhibition." },
    [GENOTYPE_PHENOTYPE.NM]:  { auc_fold:1.0, freq_pct:65,note:"Normal activation of prodrugs (clopidogrel, voriconazole)." },
    [GENOTYPE_PHENOTYPE.UM]:  { auc_fold:0.5, freq_pct:6, note:"Ultra-rapid; reduced PPI efficacy; possible increased clopidogrel bleeding risk." },
  },
  CYP2C9: {
    [GENOTYPE_PHENOTYPE.PM]:  { auc_fold:3.5, freq_pct:2, note:"Warfarin/phenytoin accumulation — markedly reduced maintenance dose. Highest bleeding risk." },
    [GENOTYPE_PHENOTYPE.IM]:  { auc_fold:1.8, freq_pct:12,note:"Reduced warfarin clearance; dose reduction ~25-50% vs NM." },
    [GENOTYPE_PHENOTYPE.NM]:  { auc_fold:1.0, freq_pct:82,note:"Standard warfarin dosing." },
    [GENOTYPE_PHENOTYPE.UM]:  { auc_fold:0.7, freq_pct:4, note:"Rare. Standard or slightly increased dose." },
  },
  CYP2B6: {
    [GENOTYPE_PHENOTYPE.PM]:  { auc_fold:3.5, freq_pct:null, note:"Reduced CYP2B6 activity; efavirenz parent exposure rises and inactive 8-hydroxyefavirenz formation falls." },
    [GENOTYPE_PHENOTYPE.IM]:  { auc_fold:2.0, freq_pct:null, note:"Intermediate CYP2B6 activity." },
    [GENOTYPE_PHENOTYPE.NM]:  { auc_fold:1.0, freq_pct:null, note:"Normal CYP2B6 activity." },
    [GENOTYPE_PHENOTYPE.UM]:  { auc_fold:0.5, freq_pct:null, note:"Higher CYP2B6 activity; lower parent exposure for sensitive substrates." },
  },
  CYP3A5: {
    [GENOTYPE_PHENOTYPE.PM]:  { auc_fold:1.8, freq_pct:null, note:"CYP3A5 non-expresser status. Tacrolimus concentration/dose is higher than in expressers; standard starting dose is usually closer than expresser dosing." },
    [GENOTYPE_PHENOTYPE.IM]:  { auc_fold:0.7, freq_pct:null, note:"CYP3A5 expresser/intermediate status. Tacrolimus dose requirements are often higher; use therapeutic drug monitoring." },
    [GENOTYPE_PHENOTYPE.NM]:  { auc_fold:1.0, freq_pct:null, note:"Reference CYP3A5 phenotype for this model." },
    [GENOTYPE_PHENOTYPE.UM]:  { auc_fold:0.5, freq_pct:null, note:"High CYP3A5 expression/activity context; sensitive CYP3A5 substrates may require higher exposure-guided dosing." },
  },
  CYP2C8: {
    [GENOTYPE_PHENOTYPE.PM]:  { auc_fold:2.0, freq_pct:null, note:"Reduced CYP2C8 activity; sensitive substrates such as pioglitazone, repaglinide, montelukast, and hydroxychloroquine may have higher exposure." },
    [GENOTYPE_PHENOTYPE.IM]:  { auc_fold:1.4, freq_pct:null, note:"Intermediate CYP2C8 activity; modest substrate exposure increase possible." },
    [GENOTYPE_PHENOTYPE.NM]:  { auc_fold:1.0, freq_pct:null, note:"Normal CYP2C8 activity." },
    [GENOTYPE_PHENOTYPE.UM]:  { auc_fold:0.8, freq_pct:null, note:"Higher CYP2C8 activity context; substrate exposure may be lower." },
  },
  CYP2A6: {
    [GENOTYPE_PHENOTYPE.PM]:  { auc_fold:3.0, freq_pct:null, note:"Reduced CYP2A6 activity; nicotine and cotinine formation/clearance shift, often lowering smoking intensity but raising nicotine exposure per cigarette." },
    [GENOTYPE_PHENOTYPE.IM]:  { auc_fold:1.6, freq_pct:null, note:"Intermediate CYP2A6 activity; slower nicotine clearance." },
    [GENOTYPE_PHENOTYPE.NM]:  { auc_fold:1.0, freq_pct:null, note:"Normal CYP2A6 activity." },
    [GENOTYPE_PHENOTYPE.UM]:  { auc_fold:0.7, freq_pct:null, note:"Higher CYP2A6 activity; faster nicotine clearance." },
  },
  NAT2: {
    [GENOTYPE_PHENOTYPE.PM]:  { auc_fold:2.0, freq_pct:null, note:"Slow acetylator phenotype; isoniazid and hydralazine exposure/toxicity risk can rise while some efficacy/toxicity tradeoffs differ by indication." },
    [GENOTYPE_PHENOTYPE.IM]:  { auc_fold:1.4, freq_pct:null, note:"Intermediate acetylator phenotype." },
    [GENOTYPE_PHENOTYPE.NM]:  { auc_fold:1.0, freq_pct:null, note:"Reference acetylator phenotype for this model." },
    [GENOTYPE_PHENOTYPE.UM]:  { auc_fold:0.7, freq_pct:null, note:"Rapid acetylator phenotype; lower exposure for NAT2 substrates." },
  },
  SLCO1B1: {
    [GENOTYPE_PHENOTYPE.PM]:  { auc_fold:2.5, freq_pct:null, note:"Decreased OATP1B1 hepatic uptake. Simvastatin acid and several statins can have higher systemic exposure and higher muscle-symptom risk." },
    [GENOTYPE_PHENOTYPE.IM]:  { auc_fold:1.5, freq_pct:null, note:"Decreased/intermediate OATP1B1 function; statin exposure may rise." },
    [GENOTYPE_PHENOTYPE.NM]:  { auc_fold:1.0, freq_pct:null, note:"Normal OATP1B1 function." },
    [GENOTYPE_PHENOTYPE.UM]:  { auc_fold:0.8, freq_pct:null, note:"Higher OATP1B1 uptake context; systemic statin exposure may be lower." },
  },
  ABCG2: {
    [GENOTYPE_PHENOTYPE.PM]:  { auc_fold:2.0, freq_pct:null, note:"Reduced BCRP/ABCG2 efflux. Rosuvastatin and sulfasalazine exposure can rise; gout/urate context may also matter." },
    [GENOTYPE_PHENOTYPE.IM]:  { auc_fold:1.4, freq_pct:null, note:"Intermediate BCRP/ABCG2 function." },
    [GENOTYPE_PHENOTYPE.NM]:  { auc_fold:1.0, freq_pct:null, note:"Normal BCRP/ABCG2 function." },
  },
  VKORC1: {
    [GENOTYPE_PHENOTYPE.PM]:  { auc_fold:1.8, freq_pct:null, note:"Warfarin-sensitive VKORC1 context; lower maintenance dose is usually needed for the same INR target." },
    [GENOTYPE_PHENOTYPE.IM]:  { auc_fold:1.3, freq_pct:null, note:"Intermediate warfarin sensitivity context." },
    [GENOTYPE_PHENOTYPE.NM]:  { auc_fold:1.0, freq_pct:null, note:"Reference VKORC1 warfarin sensitivity context." },
    [GENOTYPE_PHENOTYPE.UM]:  { auc_fold:0.8, freq_pct:null, note:"Relative warfarin-resistant VKORC1 context; higher dose may be required, guided by INR." },
  },
  CYP4F2: {
    [GENOTYPE_PHENOTYPE.PM]:  { auc_fold:0.9, freq_pct:null, note:"Reduced vitamin K oxidation can modestly increase warfarin dose requirement; effect is smaller than VKORC1/CYP2C9." },
    [GENOTYPE_PHENOTYPE.IM]:  { auc_fold:0.95, freq_pct:null, note:"Intermediate CYP4F2 vitamin K oxidation context." },
    [GENOTYPE_PHENOTYPE.NM]:  { auc_fold:1.0, freq_pct:null, note:"Normal CYP4F2 vitamin K oxidation." },
  },
  DPYD: {
    [GENOTYPE_PHENOTYPE.PM]:  { auc_fold:20.0, freq_pct:null, note:"Very low/absent DPYD activity; fluoropyrimidine toxicity risk can be life-threatening." },
    [GENOTYPE_PHENOTYPE.IM]:  { auc_fold:2.0, freq_pct:null, note:"Reduced DPYD activity; fluoropyrimidine starting dose usually requires major reduction." },
    [GENOTYPE_PHENOTYPE.NM]:  { auc_fold:1.0, freq_pct:null, note:"Normal DPYD activity." },
  },
  TPMT: {
    [GENOTYPE_PHENOTYPE.PM]:  { auc_fold:20.0, freq_pct:null, note:"Very low/absent TPMT activity; thiopurine myelosuppression risk at standard doses." },
    [GENOTYPE_PHENOTYPE.IM]:  { auc_fold:2.0, freq_pct:null, note:"Reduced TPMT activity; thiopurine dose reduction needed." },
    [GENOTYPE_PHENOTYPE.NM]:  { auc_fold:1.0, freq_pct:null, note:"Normal TPMT activity." },
    [GENOTYPE_PHENOTYPE.UM]:  { auc_fold:0.5, freq_pct:null, note:"Higher methylation tendency; lower 6-TGN and possible 6-MMP shunting." },
  },
  UGT1A1: {
    [GENOTYPE_PHENOTYPE.PM]:  { auc_fold:1.7, freq_pct:null, note:"Reduced UGT1A1 glucuronidation; SN-38 or bilirubin exposure can rise depending on substrate." },
    [GENOTYPE_PHENOTYPE.IM]:  { auc_fold:1.2, freq_pct:null, note:"Intermediate UGT1A1 activity." },
    [GENOTYPE_PHENOTYPE.NM]:  { auc_fold:1.0, freq_pct:null, note:"Normal UGT1A1 activity." },
  },
  NUDT15: {
    [GENOTYPE_PHENOTYPE.PM]:  { auc_fold:20.0, freq_pct:null, note:"NUDT15 poor function; thiopurine cytotoxic nucleotide intolerance can be profound even when TPMT is normal." },
    [GENOTYPE_PHENOTYPE.IM]:  { auc_fold:2.0, freq_pct:null, note:"NUDT15 intermediate function; thiopurine dose reduction and close CBC monitoring are usually needed." },
    [GENOTYPE_PHENOTYPE.NM]:  { auc_fold:1.0, freq_pct:null, note:"Normal NUDT15 function." },
  },
};

const GENOTYPE_RISK_EFFECTS = {
  "HLA-B*15:02": {
    gene:"HLA-B",
    variant:"*15:02",
    label:"HLA-B*15:02",
    drugEffects:[
      {
        parent:"Carbamazepine",
        phenotype:"SJS/TEN risk",
        note:"HLA-B*15:02 is strongly associated with carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. CPIC recommends avoiding carbamazepine in allele-positive patients unless benefits clearly outweigh risks and no alternatives exist.",
        clinicalAction:"avoid carbamazepine; consider non-aromatic alternatives",
        evidenceRefs:["ev_carbamazepine_oxcarbazepine_hla_cpic2017"],
      },
      {
        parent:"Oxcarbazepine",
        phenotype:"SJS/TEN risk",
        note:"HLA-B*15:02 also increases oxcarbazepine SJS/TEN risk. CPIC recommends avoiding oxcarbazepine in allele-positive patients when possible.",
        clinicalAction:"avoid oxcarbazepine when possible; consider alternatives",
        evidenceRefs:["ev_carbamazepine_oxcarbazepine_hla_cpic2017"],
      },
      {
        parent:"Phenytoin",
        phenotype:"SJS/TEN risk",
        note:"HLA-B*15:02 is associated with phenytoin-induced severe cutaneous adverse reactions, especially in populations where the allele is more common. CYP2C9 still controls the exposure/dose component.",
        clinicalAction:"avoid phenytoin/fosphenytoin if possible; use CYP2C9-guided dosing if used",
        evidenceRefs:["ev_phenytoin_cyp2c9_hlab_cpic2020"],
      },
    ],
    effects:{
      [GENOTYPE_RISK_STATUS.ABSENT]: { label:"not detected", severity:"baseline", note:"Risk allele not detected. This does not remove ordinary rash or hypersensitivity risk." },
      [GENOTYPE_RISK_STATUS.PRESENT]: { label:"detected", severity:"high", note:"Risk allele detected. Severe cutaneous adverse reaction risk is elevated for specific drugs." },
    },
  },
  "HLA-A*31:01": {
    gene:"HLA-A",
    variant:"*31:01",
    label:"HLA-A*31:01",
    drugEffects:[
      {
        parent:"Carbamazepine",
        phenotype:"carbamazepine hypersensitivity risk",
        note:"HLA-A*31:01 is associated with a broader carbamazepine hypersensitivity spectrum, including maculopapular exanthema, DRESS, and SJS/TEN.",
        clinicalAction:"avoid carbamazepine when possible; if used, monitor closely",
        evidenceRefs:["ev_carbamazepine_oxcarbazepine_hla_cpic2017"],
      },
    ],
    effects:{
      [GENOTYPE_RISK_STATUS.ABSENT]: { label:"not detected", severity:"baseline", note:"Risk allele not detected. This does not remove ordinary rash or hypersensitivity risk." },
      [GENOTYPE_RISK_STATUS.PRESENT]: { label:"detected", severity:"high", note:"Risk allele detected. Carbamazepine hypersensitivity risk is elevated." },
    },
  },
  "HLA-B*57:01": {
    gene:"HLA-B",
    variant:"*57:01",
    label:"HLA-B*57:01",
    drugEffects:[
      {
        parent:"Abacavir",
        phenotype:"abacavir hypersensitivity risk",
        note:"HLA-B*57:01 predicts abacavir hypersensitivity. CPIC and product labeling recommend avoiding abacavir in allele-positive patients.",
        clinicalAction:"abacavir contraindicated; use alternative antiretroviral",
        evidenceRefs:["ev_abacavir_hlab5701_cpic2012"],
      },
      {
        parent:"Flucloxacillin",
        phenotype:"flucloxacillin-induced cholestatic liver injury",
        note:"HLA-B*57:01 is associated with flucloxacillin-induced drug-induced liver injury (delayed cholestatic hepatitis), a different organ outcome from abacavir hypersensitivity but the same risk allele. Absolute risk is low (idiosyncratic) but the relative association is strong.",
        clinicalAction:"no routine pre-test recommended; if allele known-positive, prefer alternative anti-staphylococcal agent and monitor LFTs; investigate cholestatic LFTs promptly",
        evidenceRefs:["ev_flucloxacillin_hlab5701_daly2009"],
      },
    ],
    effects:{
      [GENOTYPE_RISK_STATUS.ABSENT]: { label:"not detected", severity:"baseline", note:"Risk allele not detected; abacavir hypersensitivity risk is substantially reduced but not impossible." },
      [GENOTYPE_RISK_STATUS.PRESENT]: { label:"detected", severity:"high", note:"Risk allele detected. Abacavir should be avoided." },
    },
  },
  "HLA-B*58:01": {
    gene:"HLA-B",
    variant:"*58:01",
    label:"HLA-B*58:01",
    drugEffects:[
      {
        parent:"Allopurinol",
        phenotype:"allopurinol SCAR risk",
        note:"HLA-B*58:01 is strongly associated with allopurinol severe cutaneous adverse reactions, including SJS/TEN and DRESS. CPIC recommends allopurinol is contraindicated in allele-positive patients.",
        clinicalAction:"allopurinol contraindicated; use alternative urate-lowering strategy",
        evidenceRefs:["ev_allopurinol_hlab5801_cpic2015"],
      },
    ],
    effects:{
      [GENOTYPE_RISK_STATUS.ABSENT]: { label:"not detected", severity:"baseline", note:"Risk allele not detected. Renal function, starting dose, and clinical monitoring still matter." },
      [GENOTYPE_RISK_STATUS.PRESENT]: { label:"detected", severity:"high", note:"Risk allele detected. Allopurinol severe cutaneous reaction risk is elevated." },
    },
  },
  "G6PD deficiency": {
    gene:"G6PD",
    variant:"deficiency (class I-III)",
    label:"G6PD deficiency",
    drugEffects:[
      {
        parent:"Rasburicase",
        phenotype:"acute hemolytic anemia / methemoglobinemia",
        note:"Rasburicase is contraindicated in G6PD deficiency: oxidative stress from hydrogen peroxide can overwhelm deficient erythrocytes, causing acute hemolytic anemia and methemoglobinemia.",
        clinicalAction:"contraindicated; use another urate-lowering strategy",
        evidenceRefs:["ev_rasburicase_g6pd_cpic2014"],
      },
      {
        parent:"Primaquine",
        phenotype:"acute hemolytic anemia",
        note:"8-aminoquinolines can impose oxidative stress and trigger acute hemolysis in G6PD-deficient patients.",
        clinicalAction:"avoid unless G6PD status and specialist plan support use",
        evidenceRefs:["ev_rasburicase_g6pd_cpic2014"],
      },
      {
        parent:"Dapsone",
        phenotype:"hemolysis / methemoglobinemia",
        note:"Dapsone can cause oxidative hemolysis and methemoglobinemia, with higher risk in G6PD deficiency.",
        clinicalAction:"avoid or use close hematologic monitoring if unavoidable",
        evidenceRefs:["ev_rasburicase_g6pd_cpic2014"],
      },
      {
        parent:"Nitrofurantoin",
        phenotype:"acute hemolytic anemia",
        note:"Nitrofurantoin is an oxidative-stress drug that can precipitate hemolysis in G6PD-deficient patients.",
        clinicalAction:"avoid in known G6PD deficiency when alternatives exist",
        evidenceRefs:["ev_rasburicase_g6pd_cpic2014"],
      },
      {
        parent:"Tafenoquine",
        phenotype:"acute hemolytic anemia / methemoglobinemia",
        note:"8-aminoquinoline imposing oxidative stress; in G6PD deficiency causes severe acute hemolytic anemia. Its ~14-day half-life means hemolysis cannot be halted by stopping the drug, so the FDA requires documented adequate G6PD activity before dosing.",
        clinicalAction:"contraindicated without documented adequate G6PD activity; FDA requires G6PD testing before use",
        evidenceRefs:["ev_tafenoquine_g6pd_fda"],
      },
      {
        parent:"Chloroquine",
        phenotype:"acute hemolytic anemia",
        note:"4-aminoquinoline; can precipitate oxidative hemolysis in G6PD deficiency, though risk is generally lower than with 8-aminoquinolines at antimalarial doses.",
        clinicalAction:"use with caution and hematologic monitoring in known deficiency; consider alternatives where feasible",
        evidenceRefs:["ev_g6pd_oxidative_antimalarials"],
      },
      {
        parent:"Quinine",
        phenotype:"acute hemolytic anemia",
        note:"Antimalarial alkaloid; oxidative-stress hemolysis reported in G6PD deficiency. Also causes immune thrombocytopenia and cinchonism independent of G6PD.",
        clinicalAction:"avoid in known deficiency when alternatives exist; monitor if unavoidable",
        evidenceRefs:["ev_g6pd_oxidative_antimalarials"],
      },
      {
        parent:"Methylene Blue",
        phenotype:"hemolysis; paradoxical worsening of methemoglobinemia",
        note:"Methylene blue reduces methemoglobin via an NADPH-dependent pathway that REQUIRES G6PD. In G6PD deficiency it is both ineffective for methemoglobinemia and itself an oxidant that can precipitate hemolysis — contraindicated.",
        clinicalAction:"contraindicated in G6PD deficiency; use ascorbic acid / exchange transfusion for methemoglobinemia instead",
        evidenceRefs:["ev_methylene_blue_maoi_fda"],
      },
      {
        parent:"Sulfasalazine",
        phenotype:"oxidative hemolysis",
        note:"The sulfapyridine moiety is an oxidant sulfonamide that can trigger hemolysis in G6PD deficiency, especially at higher doses. NAT2 slow acetylators accumulate sulfapyridine and have more dose-related adverse effects generally.",
        clinicalAction:"use cautiously with CBC monitoring in known deficiency; consider mesalamine (5-ASA) alternative",
        evidenceRefs:["ev_sulfasalazine_tpmt_inhibition"],
      },
      {
        parent:"Pegloticase",
        phenotype:"acute hemolytic anemia / methemoglobinemia",
        note:"Pegloticase (PEGylated uricase) generates hydrogen peroxide while converting urate to allantoin; in G6PD deficiency this oxidant causes life-threatening hemolysis and methemoglobinemia — contraindicated.",
        clinicalAction:"contraindicated; FDA requires G6PD screening before use, especially in African, Mediterranean/Southern-European, Middle-Eastern, and South-Asian ancestry",
        evidenceRefs:["ev_pegloticase_g6pd_fda"],
      },
    ],
    effects:{
      [GENOTYPE_RISK_STATUS.ABSENT]: { label:"normal G6PD", severity:"baseline", note:"Normal G6PD activity assumed. Ordinary precautions apply; this does not exclude other causes of hemolysis." },
      [GENOTYPE_RISK_STATUS.PRESENT]: { label:"G6PD deficient", severity:"high", note:"G6PD deficiency present. Oxidative drugs can trigger acute hemolytic anemia; rasburicase is contraindicated." },
    },
  },
  "MT-RNR1 m.1555A>G": {
    gene:"MT-RNR1",
    variant:"m.1555A>G / m.1494C>T / m.1095T>C",
    label:"MT-RNR1 ototoxicity-risk variant",
    drugEffects:[
      {
        parent:"Gentamicin",
        phenotype:"irreversible aminoglycoside ototoxicity",
        note:"MT-RNR1 risk variants markedly increase risk of irreversible aminoglycoside-induced sensorineural hearing loss, which can occur at therapeutic serum levels.",
        clinicalAction:"avoid aminoglycosides unless no safe alternative exists",
        evidenceRefs:["ev_aminoglycoside_mtrnr1_cpic2021"],
      },
      {
        parent:"Amikacin",
        phenotype:"irreversible aminoglycoside ototoxicity",
        note:"MT-RNR1 risk variants markedly increase aminoglycoside ototoxicity risk, including with amikacin.",
        clinicalAction:"avoid; use an alternative antibiotic where possible",
        evidenceRefs:["ev_aminoglycoside_mtrnr1_cpic2021"],
      },
      {
        parent:"Tobramycin",
        phenotype:"irreversible aminoglycoside ototoxicity",
        note:"MT-RNR1 risk variants markedly increase aminoglycoside ototoxicity risk, including with tobramycin.",
        clinicalAction:"avoid; use an alternative antibiotic where possible",
        evidenceRefs:["ev_aminoglycoside_mtrnr1_cpic2021"],
      },
      {
        parent:"Streptomycin",
        phenotype:"irreversible aminoglycoside ototoxicity",
        note:"MT-RNR1 risk variants markedly increase aminoglycoside ototoxicity risk, including with streptomycin.",
        clinicalAction:"avoid; use an alternative antibiotic where possible",
        evidenceRefs:["ev_aminoglycoside_mtrnr1_cpic2021"],
      },
    ],
    effects:{
      [GENOTYPE_RISK_STATUS.ABSENT]: { label:"not detected", severity:"baseline", note:"MT-RNR1 risk variant not detected. A negative result does not eliminate dose- or duration-related aminoglycoside ototoxicity." },
      [GENOTYPE_RISK_STATUS.PRESENT]: { label:"detected", severity:"high", note:"MT-RNR1 risk variant present. Aminoglycosides may cause irreversible hearing loss even at therapeutic levels." },
    },
  },
  "RYR1/CACNA1S MH variant": {
    gene:"RYR1/CACNA1S",
    variant:"malignant-hyperthermia-associated variant",
    label:"Malignant hyperthermia susceptibility",
    drugEffects:[
      {
        parent:"Succinylcholine",
        phenotype:"malignant hyperthermia trigger",
        note:"In carriers of malignant-hyperthermia-associated RYR1/CACNA1S variants, succinylcholine can precipitate a life-threatening hypermetabolic crisis.",
        clinicalAction:"avoid; use non-triggering anesthesia",
        evidenceRefs:["ev_volatile_succinylcholine_ryr1_cacna1s_cpic2019"],
      },
      {
        parent:"Sevoflurane",
        phenotype:"malignant hyperthermia trigger",
        note:"Sevoflurane is a potent volatile anesthetic and malignant hyperthermia trigger in susceptible RYR1/CACNA1S variant carriers.",
        clinicalAction:"avoid; use non-triggering anesthesia",
        evidenceRefs:["ev_volatile_succinylcholine_ryr1_cacna1s_cpic2019"],
      },
      {
        parent:"Isoflurane",
        phenotype:"malignant hyperthermia trigger",
        note:"Isoflurane is a potent volatile anesthetic and malignant hyperthermia trigger in susceptible RYR1/CACNA1S variant carriers.",
        clinicalAction:"avoid; use non-triggering anesthesia",
        evidenceRefs:["ev_volatile_succinylcholine_ryr1_cacna1s_cpic2019"],
      },
      {
        parent:"Desflurane",
        phenotype:"malignant hyperthermia trigger",
        note:"Desflurane is a potent volatile anesthetic and malignant hyperthermia trigger in susceptible RYR1/CACNA1S variant carriers.",
        clinicalAction:"avoid; use non-triggering anesthesia",
        evidenceRefs:["ev_volatile_succinylcholine_ryr1_cacna1s_cpic2019"],
      },
    ],
    effects:{
      [GENOTYPE_RISK_STATUS.ABSENT]: { label:"no MH-associated variant", severity:"baseline", note:"No MH-associated RYR1/CACNA1S variant detected. A negative genotype does not fully exclude malignant hyperthermia susceptibility; personal and family history still matter." },
      [GENOTYPE_RISK_STATUS.PRESENT]: { label:"MH-susceptible", severity:"high", note:"Malignant-hyperthermia-associated variant present. Potent volatile anesthetics and succinylcholine can trigger a life-threatening crisis." },
    },
  },
  "HLA-B*13:01": {
    gene:"HLA-B",
    variant:"*13:01",
    label:"HLA-B*13:01",
    drugEffects:[
      {
        parent:"Dapsone",
        phenotype:"dapsone hypersensitivity syndrome (DHS / DRESS)",
        note:"HLA-B*13:01 is strongly associated with dapsone hypersensitivity syndrome — a delayed (typically 4-6 week) DRESS-type reaction with fever, rash, hepatitis and eosinophilia; reported mortality ~10%. Immune-mediated and INDEPENDENT of the dose-dependent hemolysis/methemoglobinemia hazard, which tracks G6PD (see G6PD card).",
        clinicalAction:"avoid dapsone in allele-positive patients when alternatives exist; if used, counsel on DHS and monitor closely through weeks 1-8",
        evidenceRefs:[
          "ev_dapsone_hlab1301_zhang2013",
          "ev_dapsone_hlab1301_krismawati2020"
        ],
      },
    ],
    effects:{
      [GENOTYPE_RISK_STATUS.ABSENT]:{
        label:"not detected",
        severity:"baseline",
        note:"Risk allele not detected; DHS risk substantially reduced but ordinary dapsone hypersensitivity/hemolysis precautions still apply."
      },
      [GENOTYPE_RISK_STATUS.PRESENT]:{
        label:"detected",
        severity:"high",
        note:"Risk allele detected. Dapsone hypersensitivity syndrome risk markedly elevated (GWAS OR ~20). Largely absent in European/African ancestry; common in East/Southeast Asian and Indian populations."
      },
    },
  },
  "HLA-A*32:01": {
    gene:"HLA-A",
    variant:"*32:01",
    label:"HLA-A*32:01",
    drugEffects:[
      {
        parent:"Vancomycin",
        phenotype:"vancomycin-induced DRESS / liver injury",
        note:"HLA-A*32:01 is strongly associated with vancomycin-induced DRESS (drug reaction with eosinophilia and systemic symptoms), frequently with hepatocellular liver injury. In one cohort ~83% of vancomycin-DRESS cases carried the allele vs 0% of tolerant controls; ~19% of allele-positive patients developed DRESS within 4 weeks of prolonged IV exposure.",
        clinicalAction:"consider HLA-A*32:01 testing before planned prolonged IV vancomycin; if positive, weigh alternative antibiotic and monitor eosinophils/LFTs/rash weeks 1-4",
        evidenceRefs:["ev_vancomycin_hla_a3201_konvinse2019"],
      },
    ],
    effects:{
      [GENOTYPE_RISK_STATUS.ABSENT]:{
        label:"not detected",
        severity:"baseline",
        note:"Risk allele not detected; DRESS risk reduced but not zero — clinical vigilance during prolonged therapy still applies."
      },
      [GENOTYPE_RISK_STATUS.PRESENT]:{
        label:"detected",
        severity:"high",
        note:"Risk allele detected. Vancomycin-induced DRESS risk elevated, particularly with IV therapy beyond ~1-2 weeks."
      },
    },
  },
};

// activeGenotype — user-selected metabolizer phenotype per enzyme (runtime state)
// Format: { CYP2D6: 'normal_metabolizer', CYP2C19: 'normal_metabolizer', CYP2C9: 'normal_metabolizer' }
let activeGenotype = {
  CYP2D6:  GENOTYPE_PHENOTYPE.NM,
  CYP2C19: GENOTYPE_PHENOTYPE.NM,
  CYP2C9:  GENOTYPE_PHENOTYPE.NM,
  CYP2B6:  GENOTYPE_PHENOTYPE.NM,
  CYP3A5:  GENOTYPE_PHENOTYPE.NM,
  CYP2C8:  GENOTYPE_PHENOTYPE.NM,
  CYP2A6:  GENOTYPE_PHENOTYPE.NM,
  NAT2:    GENOTYPE_PHENOTYPE.NM,
  SLCO1B1: GENOTYPE_PHENOTYPE.NM,
  ABCG2:   GENOTYPE_PHENOTYPE.NM,
  VKORC1:  GENOTYPE_PHENOTYPE.NM,
  CYP4F2:  GENOTYPE_PHENOTYPE.NM,
  DPYD:    GENOTYPE_PHENOTYPE.NM,
  TPMT:    GENOTYPE_PHENOTYPE.NM,
  UGT1A1:  GENOTYPE_PHENOTYPE.NM,
  NUDT15:  GENOTYPE_PHENOTYPE.NM,
  "HLA-B*15:02": GENOTYPE_RISK_STATUS.ABSENT,
  "HLA-A*31:01": GENOTYPE_RISK_STATUS.ABSENT,
  "HLA-B*57:01": GENOTYPE_RISK_STATUS.ABSENT,
  "HLA-B*58:01": GENOTYPE_RISK_STATUS.ABSENT,
  "G6PD deficiency": GENOTYPE_RISK_STATUS.ABSENT,
  "MT-RNR1 m.1555A>G": GENOTYPE_RISK_STATUS.ABSENT,
  "RYR1/CACNA1S MH variant": GENOTYPE_RISK_STATUS.ABSENT,
  "HLA-B*13:01": GENOTYPE_RISK_STATUS.ABSENT,
  "HLA-A*32:01": GENOTYPE_RISK_STATUS.ABSENT,
};

// ── STUDY_DB ──
// First-class evidence entities. One study can support multiple graph edges.
// Contradictory evidence is explicitly tracked — real pharmacology disagrees.
//
// IMPORTANT: Every entry here has been curated from primary literature or
// regulatory documents. PMIDs marked verify:true should be independently
// confirmed before clinical use. AI hallucination risk applies — human
// pharmacist/physician review required before any clinical application.
//
